Cerulean doses first patient in Phase I/IIa trial of CRLX301 to treat advanced solid tumors
The company uses its Dynamic Tumor Targeting Platform to create a portfolio of nanoparticle-drug conjugates (NDCs) designed to selectively attack tumor cells, reduce toxicity by sparing the body’s
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.